We support:

- Biometrics
- Clinical
- Epidemiology
- HEOR
- HTA
- Late Phase
- Market Access
- Medical Affairs

We analyse data for:

- Reimbursement dossiers (NICE, G-BA)
- Post-approval reporting (PASS, PAES)
- Publication & marketing
- Clinical development

We specialise in:

- Observational data
- Patient / disease registries
- Systematic reviews
- Network meta-analyses / ITC
- Event prediction / forecasting
- Data mining & machine learning
- Primary reporting of phase I-IV trials

Email us at bd@numerus.com
or contact one of our offices:

Germany
Numerus GmbH
Tel: +49 (0) 7071 549 110

Switzerland
Numerus Analytics AG
Tel: +41 (0) 61 271 34 17

United Kingdom
Numerus Ltd
Tel: +44 (0) 118 466 0297

Clinical Development

Expert statistical design, analysis & reporting
of phase I - IV trials

Health Technology Assessment

Analytical support for HTA dossiers
including NICE & G-BA submissions

Real World Evidence

Turning real world data
into real world evidence

numerus

Analytical expertise for clinical data

www.numerus.com

Safeguard your phase I-IV development

Working with you, our statisticians carefully review your study's unique needs and determine the most effective way to analyse and present your data.

We are creative thinkers with in depth experience in the design, analysis and reporting of phase I-IV clinical trials. You can be confident that all work performed adheres to ICH-GCP, regulatory standards and our own rigorous internal operating procedures.

Companies worldwide trust Numerus to provide high quality, strategic analytical support.

Ensure your data is dossier ready

Requirements for HTA approval can be vastly different from those required by regulators. Statisticians therefore need to embrace a very different skill set from those working within clinical development.

Numerus has the experience and expertise to provide the analyses you need, on time and to the highest quality.

Our statisticians are internationally located, provide multi-lingual support and have a solid understanding of country-specific guidelines.

When speed, accuracy and quality are paramount you can depend on Numerus to deliver.

Maximise your data's potential

Real world evidence provides vital information that bridges the gap between the controlled environment of the randomised clinical trial and the reality of the real world. However, getting the most from real world data is not without its own unique set of challenges.

Numerus has been working with real world data for more than 12 years. Our statisticians have the experience, statistical skill, imagination and flexibility to extract the greatest possible value from your data.

From initial design to final analysis, we turn your real world data into real world evidence.

Clinical Development

- Protocol
- Sample size calculation
- Analysis plan
- Statistical analysis
- DMC support
- ISS / ISE

Health Technology Assessment

- G-BA, NICE & HAS dossier analysis
- SLR / data extraction
- Evidence synthesis
- Network meta-analysis
- Indirect treatment comparison
- Bayesian belief network / DAG
- Event forecasting & prediction

Real World Evidence

- Design & analysis of patient / drug registry
- Analysis of primary care & claims data
- Adjustment for confounding & selection bias
- Response / diagnostic prediction modelling
- Adjustment for treatment switching
- Data mining & machine learning